Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.
Vecabrutinib, a reversible, noncovalent Bruton’s tyrosine kinase inhibitor, exhibited evidence of clinical activity in adults with B-cell malignancies without producing any grade ≥3 treatment-related adverse events.
Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.
Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.
Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.
Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.
Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.
Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.